NNVC AMEX
NanoViricides, Inc.
1W: -11.1%
1M: +9.4%
3M: -14.7%
YTD: +5.8%
1Y: -11.1%
3Y: -12.3%
5Y: -74.8%
$1.28
+0.02 (+1.59%)
Weekly Expected Move ±17.8%
$1
$1
$1
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-09-15
Earliest Filing
2024-04-05
Latest Filing
partner: 6
licensee: 1
Counterparties (Filed by NNVC)
7 relationshipsCompanies named in NNVC's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| EF Hutton LLC | — | partner | Sole sales agent for the At Market Issuance Sales Agreement | 2024-04-05 | View |
| Benchmark Investments, Inc. | — | partner | Parent entity of former sales agent Kingswood Capital Markets | 2024-04-05 | View |
| McCarter & English, LLP | — | partner | Legal counsel providing opinion on the Sales Agreement | 2024-04-05 | View |
| TheraCour Pharma, Inc. | — | partner | Exclusive worldwide license agreement for coronavirus treatment development with milestone payments | 2024-02-16 | View |
| TheraCour | — | partner | Exclusive worldwide license agreement for coronavirus treatment development with milestone payments | 2024-02-16 | View |
| Karveer Meditech Private Limited | — | licensee | NanoViricides granted an exclusive license for NV-CoV-2 and NV-CoV-2-R in India, with Karveer sponsoring clinical trials | 2023-03-31 | View |
| TheraCour Pharma, Inc. | — | partner | Exclusive worldwide license agreement for coronavirus treatment development and manufacturing | 2021-09-15 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-29 | Officer/Director Change; Exhibits | View | |
| 2026-07-30 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-07-17 | Material Agreement; Exhibits | Agreement | View |
| 2026-05-21 | Regulation FD | View | |
| 2026-05-20 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2025-11-26 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-11-14 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-10-01 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-12-12 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-08-09 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-04-05 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2024-02-16 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2024-01-19 | Submission of Matters to a Vote of Security Holders | View | |
| 2023-11-07 | Other Events; Financial Statements and Exhibits | View | |
| 2023-09-01 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2023-05-25 | Other Events; Financial Statements and Exhibits | View | |
| 2023-03-31 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2023-02-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2022-12-22 | Submission of Matters to a Vote of Security Holders; Other Events | View | |
| 2021-11-26 | Submission of Matters to a Vote of Security Holders | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR